FDA Authorizes Autonomous Blood-Drawing Robot for Outpatient Use

The FDA cleared the Aletta device, the first robotic system that can independently draw blood without a hands-on operator, using infrared light and Doppler ultrasound to locate veins. One trained phlebotomist can supervise up to three devices simultaneously, potentially easing staffing shortages. In a multicenter study, the device achieved a 94.5% first-stick success rate when a suitable vein was identified, with only mild adverse events reported.

The Aletta’s clearance marks a shift in routine outpatient care, where blood draws have long depended on skilled human hands. Its design combines near-infrared light and Doppler ultrasound to map veins before any needle contact, then automates the entire draw sequence—from tourniquet to bandage—once a suitable vessel is confirmed. Supervising staff still start each session and check tube order and fill levels afterward. The device also includes safety features: it can abort the procedure if sensors detect unsafe conditions, and the needle detaches automatically if a patient moves excessively.

Clinical testing showed strong performance across challenging populations, including older adults and those with hard-to-access veins. The reported first-stick success rate of 94.5% when a vein was found, along with a low rate of mild adverse events, suggests the technology could complement human phlebotomists rather than replace them. Patient feedback indicated most experienced similar or less pain, and a majority expressed at least some preference for the robotic approach.